Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study

Vox Sanguinis

Volumn 112, Issue 3, 2017, Pages 210-218

  Cancelas, J A ^a   Gottschall, J L ^b   Rugg, N ^a   Graminske, S ^b   Schott, M A ^c   North, A ^c   Huang, N ^c   Mufti, N ^c   Erickson, A ^c   Rico, S ^c   Corash, L ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c CERUS CORPORATION   (United States)

Author keywords

amustaline; pathogen reduction; red blood cells; S 303; viability

Indexed keywords

AMUSTALINE; (N,N-BIS(2-CHLOROETHYL))-2-AMINOETHYL-3-((ACRIDIN-9-YL)AMINO)PROPIONATE; ACRIDINE DERIVATIVE; CHLORMETHINE DERIVATIVE; CHROMIUM; TECHNETIUM;

ADULT; AGED; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATHOGEN REDUCTION SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE BLIND PROCEDURE; ADVERSE EFFECTS; AREA UNDER THE CURVE; BLOOD STORAGE; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; ERYTHROCYTE; ERYTHROCYTE COUNT; HALF LIFE TIME; HEMATOMA; ISOTOPE LABELING; METABOLISM; MICROBIAL VIABILITY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; TIME FACTOR; VIRUS INACTIVATION; YOUNG ADULT;

ACRIDINES; ADULT; AGED; AREA UNDER CURVE; BLOOD PRESERVATION; CELL SURVIVAL; CHROMIUM ISOTOPES; CROSS-OVER STUDIES; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HALF-LIFE; HEMATOMA; HUMANS; ISOTOPE LABELING; MALE; MICROBIAL VIABILITY; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; ROC CURVE; SINGLE-BLIND METHOD; TECHNETIUM; TIME FACTORS; VIRUS INACTIVATION; YOUNG ADULT;

EID: 85013498005     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12500     Document Type: Article

References (32)

1. Kleinman S, Glynn SA, Busch M, et al.: The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 2005; 45:469–479
2. Tilak R, Ray S, Tilak VW, et al.: Dengue, chikungunya… and the missing entity - Zika fever: a new emerging threat. Med J Armed Forces India 2016; 72:157–163
3. Holtzclaw A, Mrsic Z, Managbanag J, et al.: Transfusion-transmitted malaria not preventable by current blood donor screening guidelines: a case report. Transfusion 2016; 56:2221–2214
4. Stramer SL, Dodd RY, AABB transfusion-transmitted diseases emerging infectious diseases subgroup: Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013; 53:2375–2383
5. Kopolovic I, Ostro J, Tsubota H, et al.: A systematic review of transfusion-associated graft-versus-host disease. Blood 2015; 126:406–414
6. Kleinman S, Stassinopoulos A: Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 2015; 55:2983–3000
7. Salunkhe V, van der Meer PF, de Korte D, et al.: Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015; 52:19–34
8. Seltsam A, Muller TH: Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162:442–454
9. Cazenave JP, Isola H, Waller C, et al.: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622–629
10. Osselaer JC, Doyen C, Defoin L, et al.: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412–1422
11. Lin L, Cook DN, Wiesehahn GP, et al.: Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423–435
12. Corash L: Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001; 8:138–145
13. Dupuis K, Bernard K, Jones S, et al.: Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates. Blood 2003; 102(Suppl 1):816a
14. Hanson D, Propst M, Dupuis K, et al.: High titer leukocyte inactivation in INTERCEPT red blood cells (RBC) [abstract]. Vox Sang 2001; 81:101a
15. Mikovits JA, Hagen K, Liu W, et al.: Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system [abstract]. Rev Antivir Ther Infect Dis 2010; 8:36–37
16. Mufti NA, Erickson AC, North AK, et al.: Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38:14–19
17. Rios JA, Hambleton J, Viele M, et al.: Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46:1778–1786
18. Cancelas JA, Dumont L, Herschel L, et al.: A randomized, controlled, 2-period crossover study of recovery and lifespan of radiolabeled autologous 35-day old red blood cells prepared with a modified S-303 treatment for pathogen inactivation [abstract]. Vox Sang 2008; 95(Suppl 1):8–9
19. Benjamin RJ, McCullough J, Mintz PD, et al.: Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45:1739–1749
20. Conlan MG, Vichinsky E, Snyder E, et al.: S-303 pathogen inactivated red blood cells in patients with hemoglobinopathies participating in chronic transfusion programs: preliminary safety and efficacy results [abstract]. Vox Sang 2005; 89(Suppl 1):121
21. Conlan MG, Stassinopoulos A, Garratty G, et al.: Antibody formation to S-303-treated RBCs in the setting of chronic RBC transfusion [abstract]. Blood 2004; 104:112–113
22. North A, Ciaravino V, Mufti N, et al.: Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011; 51:2208–2218
23. Cancelas JA, Dumont LJ, Rugg N, et al.: Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011; 51:2367–2376
24. AuBuchon JP, Cancelas JA, Herschel L, et al.: In vitro and in vivo evaluation of LEUKOSEP HRC-600-C leukoreduction filtration system for red cells. Transfusion 2006; 46:1311–1315
25. Moroff G, Sohmer PR, Button LN: Proposed standardization of methods for determining the 24-hour survival of stored red cells. Transfusion 1984; 24:109–114
26. Recommended method for radioisotope red-cell survival studies: International Committee for Standardization in Haematology. Br J Haematol 1980; 45:659–666
27. Handin RI, Lux SE, Stossel TP: (2003). Appendix 25 and 31. Blood: Principles and Practice of Hematology. Philadelphia Lippincott Williams & Wilkins: 2216, 2219
28. Kuruvilla DJ, Nalbant D, Widness JA, et al.: Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells. Transfusion 2014; 54:2724–2729
29. Kwon Y: Pharmacokinetic study design and data interpretation; in Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists, Chapter 2. New York, NY, Kluwer Academic/Plenum Publishers, 2001:3–28
30. Garby L, Mollison PL: Deduction of mean red-cell life-span from 51Cr survival curves. Br J Haematol 1971; 20:527–536
31. Bentley SA, Glass HI, Lewis SM, et al.: Elution correction in 51Cr red cell survival studies. Br J Haematol 1974; 26:179–184
32. Mollison PL: Methods of determining the posttransfusion survival of stored red cells. Transfusion 1984; 24:93–96